CY1111699T1 - Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη - Google Patents

Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη

Info

Publication number
CY1111699T1
CY1111699T1 CY20111100674T CY111100674T CY1111699T1 CY 1111699 T1 CY1111699 T1 CY 1111699T1 CY 20111100674 T CY20111100674 T CY 20111100674T CY 111100674 T CY111100674 T CY 111100674T CY 1111699 T1 CY1111699 T1 CY 1111699T1
Authority
CY
Cyprus
Prior art keywords
therapeas
pirfenidonis
age
providing
pirfenidone
Prior art date
Application number
CY20111100674T
Other languages
Greek (el)
English (en)
Inventor
Williamson Ziegler Bradford
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39259551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111699(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of CY1111699T1 publication Critical patent/CY1111699T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2205/00—General identification or selection means
    • A61J2205/50—General identification or selection means using icons or symbolic figures, e.g. by a graphical representation symbolising the type of pathology or the organ by an image

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CY20111100674T 2006-12-18 2011-07-12 Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη CY1111699T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87059306P 2006-12-18 2006-12-18
EP07865831A EP2124945B1 (en) 2006-12-18 2007-12-18 Method of providing pirfenidone therapy to a patient

Publications (1)

Publication Number Publication Date
CY1111699T1 true CY1111699T1 (el) 2015-10-07

Family

ID=39259551

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100674T CY1111699T1 (el) 2006-12-18 2011-07-12 Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη

Country Status (14)

Country Link
US (9) US7767700B2 (https=)
EP (4) EP2338489B1 (https=)
JP (1) JP2010513320A (https=)
AT (1) ATE506060T1 (https=)
CA (1) CA2667654C (https=)
CY (1) CY1111699T1 (https=)
DE (1) DE602007014113D1 (https=)
DK (1) DK2124945T3 (https=)
ES (3) ES2395396T3 (https=)
MX (1) MX2009006526A (https=)
PL (2) PL3053580T3 (https=)
PT (1) PT2124945E (https=)
SI (1) SI2124945T1 (https=)
WO (1) WO2008077068A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2124945T1 (sl) 2006-12-18 2011-08-31 Intermune Inc Postopek dajanja terapije s pirfenidonom pacientu
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AU2012205256B2 (en) * 2008-11-10 2015-05-28 Intermune, Inc. Pirfenidone Treatment for Patients with Atypical Liver Function
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) * 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
USD731783S1 (en) 2014-04-16 2015-06-16 Abbvie Inc. Template for a prescription medicine container
USD731171S1 (en) 2013-10-07 2015-06-09 Abbvie Inc. Template for a prescription medicine container
USD731782S1 (en) 2013-10-07 2015-06-16 Abbvie Inc. Template for a prescription medicine container
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
US20190070145A1 (en) * 2016-03-22 2019-03-07 Mayo Foundation For Medical Education And Research Using fatty acid synthase inhibitors to treat fibrosis
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019028062A1 (en) 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
USD930973S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
USD930974S1 (en) 2018-03-22 2021-09-21 Abbvie Inc. Child-resistant medication container
US11052021B2 (en) 2018-03-22 2021-07-06 Abbvie Inc. Medicine container, method of assembling the container, and method of dispensing the medicine from the container
USD882243S1 (en) 2018-03-26 2020-04-28 Abbvie Inc. Child-resistant medication container assembly
US11406563B2 (en) * 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
KR20220109439A (ko) 2019-12-04 2022-08-04 이도르시아 파마슈티컬스 리미티드 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합
GB2589635B (en) 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
WO2022194941A1 (en) * 2021-03-17 2022-09-22 Actelion Pharmaceuticals Ltd Pharmaceutical dosage system
CN119630395A (zh) 2022-02-28 2025-03-14 努福米克斯技术有限公司 用于治疗特发性肺纤维化的组合物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US695044A (en) * 1901-12-28 1902-03-11 Albert E Gibson Non-refillable bottle.
SE9502370D0 (sv) 1995-06-30 1995-06-30 Astra Ab Blister pack, especially for drugs, as well as method and device in manufacturing the same
US6956044B1 (en) * 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
KR100891887B1 (ko) * 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
EP1551369A4 (en) * 2002-08-28 2007-05-09 Intermune Inc COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
CN101039957A (zh) * 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20070053877A1 (en) * 2003-08-21 2007-03-08 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AU2006276246B2 (en) * 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US20070203202A1 (en) * 2005-12-02 2007-08-30 Robinson Cynthia Y Methods of reducing adverse events associated with pirfenidone therapy
US20080003635A1 (en) * 2006-06-12 2008-01-03 Intermune, Inc. High Throughput Collagen Synthesis Assay
CN101484167B (zh) * 2006-06-15 2012-07-04 上海睿星基因技术有限公司 吡啶酮类衍生物预防和治疗放射性肺损伤的用途
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
SI2124945T1 (sl) 2006-12-18 2011-08-31 Intermune Inc Postopek dajanja terapije s pirfenidonom pacientu
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders

Also Published As

Publication number Publication date
PL2124945T3 (pl) 2011-09-30
US8420674B2 (en) 2013-04-16
US20090197923A1 (en) 2009-08-06
US7696236B2 (en) 2010-04-13
ES2882956T3 (es) 2021-12-03
DK2124945T3 (da) 2011-08-01
EP2338489B1 (en) 2016-04-27
HK1133584A1 (en) 2010-04-01
WO2008077068A1 (en) 2008-06-26
US20100324097A1 (en) 2010-12-23
PT2124945E (pt) 2011-07-01
US20190247380A1 (en) 2019-08-15
EP2471534A1 (en) 2012-07-04
SI2124945T1 (sl) 2011-08-31
HK1153647A1 (en) 2012-04-05
US20130220871A1 (en) 2013-08-29
US20080194644A1 (en) 2008-08-14
CA2667654A1 (en) 2008-06-26
EP2124945B1 (en) 2011-04-20
EP3053580B1 (en) 2021-06-30
US20200113884A1 (en) 2020-04-16
EP2338489A1 (en) 2011-06-29
ES2581844T3 (es) 2016-09-07
MX2009006526A (es) 2009-06-30
US20180140588A1 (en) 2018-05-24
US7767700B2 (en) 2010-08-03
CA2667654C (en) 2016-12-13
ATE506060T1 (de) 2011-05-15
US20160324842A1 (en) 2016-11-10
JP2010513320A (ja) 2010-04-30
EP2124945A1 (en) 2009-12-02
US20190000821A1 (en) 2019-01-03
ES2395396T3 (es) 2013-02-12
PL3053580T3 (pl) 2021-12-20
DE602007014113D1 (de) 2011-06-01
EP3053580A1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
CY1111699T1 (el) Μεθοδος παροχης θεραπειας πιρφενιδονης σε εναν ασθενη
PH12015500719A1 (en) Gdf-8-inhibitors
SI3133070T1 (sl) Eliglustat (GENZ 112638) kot inhibitor sintaze glukozilceramida za uporabo v postopku zdravljenja Fabrjyeve ali Gaucherjeve bolezni, kjer postopek obsega prilagajanje individualnega terapevtskega odmerka metabolizmu P-450 pacienta
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
PH12014500386A1 (en) Combination treatment for hepatitis c
CY1115862T1 (el) Θεραπεια με πιρφενιδονη για ασθενεις με μη φυσιολογικη ηπατικη λειτουργια
EA201101507A1 (ru) Способы лечения солидных опухолей
MX346186B (es) Inhibidores de proteina cinasas.
WO2011127070A3 (en) IRE-1α INHIBITORS
UA117556C2 (uk) Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату
BR112012032796A2 (pt) miméticos niacina, e os métodos de utilização dos mesmos
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
IN2009KN03959A (https=)
HK1231381A1 (zh) 癌症组合疗法
BR112015002183A2 (pt) processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
EA201190337A1 (ru) Способ лечения
PH12014500381A1 (en) Therapeutic methods
AR088204A1 (es) Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
AU2018333954A1 (en) Methods and compositions to inhibit dependence on opioids
CY1120920T1 (el) Συνθεσεις υψηλης δοσης βουπρενορφινης και χρηση ως αναλγητικο
CY1111919T1 (el) Ηλεκτρικο αλας της 2-((4-(1-μεθυλ-4-(πυριδιν-4-υλ)-1η-πυραζολ-3-υλ)-φαινοξυ)μεθυλ)κινολινης
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.